Carcinogenicity risk assessment supports the chronic safety of dapagliflozin, an inhibitor of sodium-glucose co-transporter 2, in the treatment of type 2 diabetes mellitus.
about
Efficacy and safety of dapagliflozin, a sodium glucose cotransporter 2 (SGLT2) inhibitor, in diabetes mellitusEfficacy, safety and regulatory status of SGLT2 inhibitors: focus on canagliflozinType 2 Diabetes Mellitus and Cancer: The Role of Pharmacotherapy.A Review on the Relationship between SGLT2 Inhibitors and Cancer.Dapagliflozin for the treatment of type 2 diabetes: a review of the literatureDapagliflozin in patients with type 2 diabetes mellitus.Assessing Bladder Cancer Risk in Type 2 Diabetes Clinical Trials: the Dapagliflozin Drug Development Program as a 'Case Study'The renal effects of SGLT2 inhibitors and a mini-review of the literature.Dapagliflozin: a review of its use in patients with type 2 diabetes.SGLT2 inhibitors and risk of cancer in type 2 diabetes: a systematic review and meta-analysis of randomised controlled trials.A Review of the Efficacy and Safety of Sodium-Glucose Cotransporter 2 Inhibitors: A Focus on Diabetic Ketoacidosis.Efficacy and safety of dapagliflozin over 1 year as add-on to insulin therapy in Japanese patients with type 2 diabetes: the DAISY (Dapagliflozin Added to patients under InSulin therapY) trial.Therapeutic Effect of Sodium Glucose Co-Transporter 2 Inhibitor Dapagliflozin on Renal Cell Carcinoma.A Predominant Oxidative Renal Metabolite of Empagliflozin in Male Mice Is Cytotoxic in Mouse Renal Tubular Cells but not Genotoxic.SGLT2 inhibitors: are they safe?Canagliflozin mediated dual inhibition of mitochondrial glutamate dehydrogenase and complex I: an off-target adverse effect.
P2860
Q26782225-49BC6339-7A76-42B3-B09E-59922A2B0EA7Q28250844-FE28F67C-F451-4B5B-9512-C4F1F537A042Q33756414-E2DA0482-7FBC-4CCD-A4C4-3ACB3A3E6811Q34181385-223D44B4-AB21-49D1-9A61-DC461B716A97Q34710819-E45E6F2B-0A8F-4216-990F-E3FC2E76760CQ35064363-08277BF2-AF57-4CE3-99F1-2A4E28172E6DQ36073447-572C11CF-59FD-4748-9FFE-A0AABB8E8FC2Q37632127-FC413FD9-DED0-4B79-A845-BA81336A0A5CQ38267346-28B9A085-332A-4F63-B6A6-1A4772D2C288Q38654762-0B9CCD90-25C7-4116-A9C2-5B98CCBD1BFDQ39355218-4B83F17C-85AC-46CB-A992-263E439B5B11Q40405896-3965F880-1085-435D-8369-224FFA5F4EC3Q41323535-6A7C5D2F-4130-4864-AF82-785861507705Q46262880-A182245D-A9B1-4089-90BF-731BD419F365Q47642298-AF105C9F-71C8-4F6E-A099-EDC61B7FC4D2Q52378681-104ED5C7-9D72-4826-89BA-F71A0690EE32
P2860
Carcinogenicity risk assessment supports the chronic safety of dapagliflozin, an inhibitor of sodium-glucose co-transporter 2, in the treatment of type 2 diabetes mellitus.
description
2014 nî lūn-bûn
@nan
2014 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
Carcinogenicity risk assessmen ...... t of type 2 diabetes mellitus.
@ast
Carcinogenicity risk assessmen ...... t of type 2 diabetes mellitus.
@en
type
label
Carcinogenicity risk assessmen ...... t of type 2 diabetes mellitus.
@ast
Carcinogenicity risk assessmen ...... t of type 2 diabetes mellitus.
@en
prefLabel
Carcinogenicity risk assessmen ...... t of type 2 diabetes mellitus.
@ast
Carcinogenicity risk assessmen ...... t of type 2 diabetes mellitus.
@en
P2093
P2860
P1433
P1476
Carcinogenicity risk assessmen ...... t of type 2 diabetes mellitus.
@en
P2093
Craig Fairchild
Evan B Janovitz
Francis Lee
Jean M Whaley
Mark Tirmenstein
Michael J Graziano
Thomas E Dorr
Timothy P Reilly
P2860
P2888
P356
10.1007/S13300-014-0053-3
P577
2014-01-29T00:00:00Z
P5875
P6179
1047270217